Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure

Federico G. Villamil, Ke‐Qin Hu, Chang‐Hong Yu, Chao‐Hung Lee, Sergio E. Rojter, Luis G. Podesta, Leonard Makowka, Stephen A. Geller, John M. Vierling – 1 November 1995 – The role of hepatitis C virus (HCV) infection in fulminant hepatic failure is controversial. The frequency of serum HCV RNA positivity in previously reported patients with fulminant hepatic failure (FHF) of indeterminate cause ranged from 0 to 12% in the United States and Europe and from 43% to 59% in Asia.

FK506 in liver transplantation for chronic hepatitis B: In vitro studies on lymphocyte activation and virus replication

Philip Y. N. Wong, George Marinos, Mark Peakman, J. Michael Tredger, Johnson Y. N. Lau, Diego Vergani, Nikolai V. Naoumov, Professor Roger Williams – 1 November 1995 – Recurrence of hepatitis B virus (HBV) in the graft is the major problem for patients with chronic HBV infection undergoing liver transplantation, which could be potentiated by the immunosuppression.

Choline deficiency: A cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation

Alan L. Buchman, Mark D. Dubin, Adib A. Moukarzel, Donald J. Jenden, Margareth Roch, Kathleen M. Rice, Jeff Gornbein, Marvin E. Ament – 1 November 1995 – Patients receiving long‐term total parenteral nutrition (TPN) develop hepatic steatosis as a complication. Our previous studies have shown this to be caused, at least in part, by choline deficiency. We studied four patients (1 man, 3 women) aged 50 ± 13 years who had low plasma‐free choline concentrations 4.8 ± 1.7 (normal, 11.4 ± 3.7 nmol/mL). The patients had received TPN for 9.7 ± 4.7 years.

Molecular dissection of the mitogenic effect of hepatocytes on cultured hepatic stellate cells

Axel M. Gressner, Birgit Lahme, Arnfried Brenzel – 1 November 1995 – The activation of proliferation of rat liver hepatic stellate cells (HSC) in cooperation with hepatocytes (PC) was studied using a coculture system and cell‐conditioned media, respectively. The proliferation of HSC was followed by incorporation of [3H] thymidine and BrdU into DNA and by DNA content per culture.

The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study

Keith D. Lindor, E. Rolland Dickson, Roberta A. Jorgensen, Monte L. Anderson, Russell H. Wiesner, Gregory J. Gores, Stephen M. Lange, Steven S. Rossi, Alan F. Hofmann, William P. Baldus – 1 October 1995 – Ursodeoxycholic acid (UDCA) and methotrexate (MTX) have both been proposed as treatments for patients with primary biliary cirrhosis (PBC). It has been suggested that a combination of the two drugs may offer advantages over either used separately. In this pilot study, we sought to evaluate the safety and efficacy of this combination for patients with PBC.

Subscribe to